Biogen plans 4 phase study: Evaluation Benifit of SPINRAZA® (NUSINERSEN) in patients thats treated with ZOLGENSMA

CAMBRIDGE, Mass., July 21, 2020 Biogen Inc. (Nasdaq: BIIB) today announced it plans to initiate a global Phase 4 clinical study, RESPOND, to examine the clinical benefit and assess the safety of SPINRAZA® (nusinersen) in infants and children with spinal muscular atrophy (SMA) who still have unmet clinical needs following treatment with gene therapy Zolgensma® (onasemnogene abeparvovec).

Vetenskapliga artiklar om spinal muskelatrofi

Publicerat av


Light a candle, let it burn. 🕯 Never give up the hope, let the darkness disapear. 🌅 Had a son with X-Linked Spinal Muscular Atrophy (SMAX2)